Long-term efficacy and safety of lorlatinib versus alectinib in anaplastic lymphoma kinase-positive advanced/metastatic non-small cell lung cancer: matching-adjusted indirect comparison - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/41392951/
Aim: Lorlatinib demonstrated superior efficacy over alectinib as a first-line treatment for ALK-positive (ALK+) advanced/metastatic non-small cell lung cancer in a matching-adjusted indirect comparison (MAIC) using 3-year follow-up data from...
Updated matching-adjusted comparison shows lorlatinib provides superior long-term progression-free survival versus alectinib in ALK-positive metastatic NSCLC, including CNS subgroups, with manageable toxicity despite higher grade ≥3 adverse events.
Microfluidic lung cancer models: Bridging clinical treatment strategies and tumor microenvironment recapitulation - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/41415904/
Lung cancer remains the leading cause of cancer-related mortality worldwide, with non-small cell lung cancer accounting for a majority of cases. Despite advances in targeted therapies and immunotherapy, challenges such...
Microfluidic lung cancer-on-a-chip models recapitulate tumor microenvironment, biomechanics, and heterogeneity better than traditional models, improving drug testing, understanding resistance, and enabling personalized, clinically relevant lung cancer treatment strategies.
Managing lorlatinib-induced weight gain through a structured exercise intervention in an ALK+ NSCLC patient: a case report - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/41357598/
This case may represent the backbone for further interventional studies aimed at determining the real efficacy of exercise intervention in preventing or controlling weight gain in this population.
Structured aerobic and resistance exercise stabilized lorlatinib-related weight gain, reduced fat mass, increased muscle mass, and improved fitness and quality of life in an ALK+ NSCLC patient, supporting non-pharmacologic management strategies.
Impact of Long-Term Structured Exercise on Body Composition in an NTRK Fusion-Positive NSCLC Patient Treated With Entrectinib - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/41342346/
Entrectinib, a first-generation TRK inhibitor, is effective in NTRK fusion-positive non-small cell lung cancer (NSCLC) but commonly induces significant weight gain. We describe the case of a 42-year-old patient with...
Structured long-term aerobic and resistance exercise safely mitigated entrectinib-associated fat gain while preserving lean mass in an NTRK-positive NSCLC patient, supporting exercise as a metabolic-protective adjunct to targeted therapy.
Lung Adenocarcinoma Presenting as Diffuse Interstitial Lung Disease: A Case Report and Literature Review - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/41261842/
Lung adenocarcinoma (LUAD) is the most common subtype of non-small-cell lung cancer and a leading cause of cancer-related mortality worldwide. Although it typically presents as a solitary pulmonary nodule or...
Heavy-smoker firefighter with cough and ILD-like imaging was diagnosed via biopsy with invasive lung adenocarcinoma; atypical diffuse presentation highlights need for early tissue sampling when ILD mimics obscure underlying malignancy.